Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
RNA terminal phosphate cyclase-like protein 1 (RCL1) is a highly conserved enzyme, structurally similar to bona fide RNA 3′-phosphate cyclases but typically deficient in actual cyclase enzymatic activity due to lack of a critical histidine residue for catalysis[1]. RCL1 is an essential nucleolar protein required for pre-rRNA processing, specifically for the maturation of 18S rRNA via cleavage at distinct processing sites, thereby supporting ribosome assembly and protein synthesis[1][2][3]. In yeast, human, and plant cells, depletion or inactivation of RCL1 impairs cell growth and ribosome biogenesis[1][3]. RCL1 has clinical relevance as a prognostic biomarker and potential tumor suppressor in hepatocellular carcinoma, where its expression inversely correlates with tumor stage and invasiveness[2]. No therapeutic agents are known to target RCL1 directly.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on RNA terminal phosphate cyclase-like protein 1 (RCL1).